AZD5363

目录号:S8019

AZD5363 Chemical Structure

Molecular Weight(MW): 428.92

AZD5363有效抑制Akt(Akt1/Akt2/3)的所有亚型,在无细胞试验中IC50为3 nM/8 nM/8 nM,对P70S6K/PKA也具有相似的抑制效果,而对ROCK1/2抑制活性较低。Phase 2。

规格 价格 库存 购买数量  
RMB 1926.33 现货
RMB 1216.65 现货
RMB 3865.98 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • G-H. Analysis of cells treated with AZD5363 (500 nM) for 24 hrs. G.Western analysis of whole cell lysates. H. Cells labeled with Annexin V-FITC for 6h were imaged. Individual points are average for replicates assessed in duplicate. Midlines are the average ± S.D. Student’s T-test.

    Cancer Res, 2016, 76(16):4752-64.. AZD5363 purchased from Selleck.

    Inhibition of PI3K and Akt by LY294002 and AZD5363 was confirmed by analyzing expression and activation status of the ribosomal protein S6 by Western blot analysis of PC-3 clone #14 cells treated with 0.5 or 5 uM AZD5363 (AZD) and 10 uM LY294002 (LY). Tubulin was used as a loading control.

    Cell Commun Signal 2014 12(1), 61. AZD5363 purchased from Selleck.

  • (A) 239 cells stably expressing Flag-IL-17RA (293-IL-17RA cell line) were treated with 2 μM AZD5363 (a pan-Akt inhibitor) and/or 50 ng/ml insulin for the indicated time periods; Western blot analysis was performed for the indicated proteins; exogenous, IL-17RA transfected into 293 cells; endogenous, endogenous IL-17RA expressed in 293 cells.

    Oncotarget, 2016, 7(12):13651-66. AZD5363 purchased from Selleck.

    LNCaP, LNCaP95, VCaP and 22Rv1 cells were transfected with control or pooled siRNA for AKT 1–3 isoforms for 36 hours. Cells were then further treated with 5 uM AZD5363 (B) for another 18 hours. Protein lysates were immunoblotted with AR (N-20), AR-V7, Pan-AKT, p-AKT(ser473) and β-Actin antibodies. Results were repeated in more than three independent experiments.

    PLoS One 2014 9(10), e108780. AZD5363 purchased from Selleck.

产品安全说明书

Akt抑制剂选择性比较

生物活性

产品描述 AZD5363有效抑制Akt(Akt1/Akt2/3)的所有亚型,在无细胞试验中IC50为3 nM/8 nM/8 nM,对P70S6K/PKA也具有相似的抑制效果,而对ROCK1/2抑制活性较低。Phase 2。
特性 AZD5363具有良好的临床前期耐受性,和AKT抑制剂的药效学特性,且不同于其他AKT抑制剂具有卓越的特性,已经进入临床开发阶段。[2]
靶点
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
ROCK2 [1]
(Cell-free assay)
3 nM 8 nM 8 nM 56 nM
体外研究

AZD5363是有效的Akt抑制剂,抑制Akt1, Akt2 和 Akt3时,IC50分别为3 nM, 8 nM 和 8 nM。PIK3CA突变的激活,肿瘤抑制基因PTEN的丢失或失活,或HER2的扩增,都与AZD5363有着显著的关系。此外,还可以看出细胞系的RAS突变状态与抗AZD5363之间的相关性。[1]AZD5363在细胞中抑制AKT底物的磷酸化,效价约为0.3〜0.8μM。AZD5363抑制182种实体和血液肿瘤细胞系中的41种细胞增殖,效价为< 3 μM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37uUlIxOCCwTR?= Mof3OkBl Mn7sbY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 NFj4WpMzPjN3MUOyNy=>
ZR75 NXvL[ph4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfoNVAxKG6P MlS1OkBl MnnMbY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 MVSyOlM2OTN{Mx?=
T74D MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;2WXoyODBibl2= NInvXZE3KGR? MmmxbY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 MoGwNlY{PTF|MkO=
1%MCF7 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DKSlQxOCCwTR?= MmfVOkBl Mk\pbY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 M3n3OVI3OzVzM{Kz
MCF7 LTED NFXqVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6yNFAhdk1? NXzSWGJPPiCm NUL0PXpWcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 MX:yOlM2OTN{Mx?=
ZR75 LTED NEPLPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCxNFAhdk1? M4SxSVYh\A>? NXXRXmM4cW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 MUGyOlM2OTN{Mx?=
T74D LTED Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\EfmQyODBibl2= NVK1XVVQPiCm NYL6RZpjcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 NHm5SIszPjN3MUOyNy=>
TamR MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HtVFQxOCCwTR?= NFXEOo83KGR? Mn;SbY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 NGHCO4kzPjN3MUOyNy=>
HCC1954 M4nJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzzNVB6OC1zLkO1JO69VQ>? NV;0fW9OPSCm Mnvj[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF? MYGyOlA6PTR5NR?=
BT474c M{T5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPNNE0yNjN3IN88US=> NH3Neog2KGR? NUPSUGV3\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G= MVKyOlA6PTR5NR?=
KPL4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHP[o8xNTFwM{Wg{txO NYrR[nI4PSCm Moi2[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF? NUfCRYRiOjZyOUW0O|U>
SKBR3 NWKyRWVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOwMVEvOzVizszN MonOOUBl NX\UO3VV\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G= NWnxZ3JsOjZyOUW0O|U>
MR49C MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPsOVJQOC13IN88US=> Mk\4OFghcA>? M37wOIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M4e3VlI2OTVzMEGy
MR49F NH7VN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi1PXkxNTVizszN NHHyS|k1QCCq M1PBbYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MXOyOVE2OTBzMh?=
NCI-H522 NYHLWoZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV2wc3FEUUN3ME2xNU4{KCkEsUKuO{kh|ryP NYnlemJoOjR7NUe2PFI>
PC-9 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfxWIFKSzVyPUmuN{ApyrFzLkKpJO69VQ>? NEixfGwzPDl3N{[4Ni=>
NCI-H522 NH;BWmpHfW6ldHnvckBCe3OjeR?= M3fOclEwPS9zMDFOwG0> MVW0M|I1KGh? NHzUd25qdmO{ZXHz[ZMhSUuWIIDoc5NxcG:{eXzheIlwdg>? MmHPNlQ6PTd4OEK=
PC-9 MXjGeY5kfGmxbjDBd5NigQ>? MWOxM|UwOTBizszN MmLkOE8zPCCq NFHxSodqdmO{ZXHz[ZMhSUuWIIDoc5NxcG:{eXzheIlwdg>? MnLhNlQ6PTd4OEK=
HGC27 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\COnI3UUN3ME2wMlQ1PSEQvF2= M121RlI1ODh6M{iy
IM95m NGPXc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwNUGg{txO MYWyOFA5QDN6Mh?=
AGS NGrCZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\UXnFjUUN3ME2wMlU2OiEQvF2= NF;C[GQzPDB6OEO4Ni=>
NCI-N87 M{n2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwMEO3JO69VQ>? MYOyOFA5QDN6Mh?=
23132/87 M4r0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LQfmlEPTB;MT62O|Eh|ryP MWSyOFA5QDN6Mh?=
MKN1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf5TmVKSzVyPUKuOFIyKM7:TR?= MWeyOFA5QDN6Mh?=
SNU-620 NWqzdYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTNwM{i0JO69VQ>? NUDFNYRMOjRyOEizPFI>
SNU-638 M2fYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfofZRKSzVyPUSuOVI{KM7:TR?= MkiwNlQxQDh|OEK=
SNU-1 NHKxVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj5TWM2OD13LkK1PEDPxE1? M2TFZVI1ODh6M{iy
SNU-601 NX2z[JdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXFSFVKSzVyPUWuPVM5KM7:TR?= MX6yOFA5QDN6Mh?=
SNU-668 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7BPWFKSzVyPU[uNFA{KM7:TR?= NUn3fphDOjRyOEizPFI>
HS746T MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLCTWM2OD14LkC4OEDPxE1? MmnzNlQxQDh|OEK=
KATO III NGjodI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrjeXZoUUN3ME23MlI3PyEQvF2= MonmNlQxQDh|OEK=
SNU-484 M2TCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WwOmlEPTB;Nz6zPVIh|ryP MX:yOFA5QDN6Mh?=
SNU-16 NYiye4l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLxTWM2OD1zMT6wPVch|ryP NVuzNVlEOjRyOEizPFI>
OCUM-1 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r0bGlEPTB;MUSuOVE2KM7:TR?= MV:yOFA5QDN6Mh?=
NUGC-3 M4D1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJzLki3N{DPxE1? NW\QbXhsOjRyOEizPFI>
AZ521 NXjseIg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LjfmlEPTB;MkWuOFQ5KM7:TR?= NHjQc3IzPDB6OEO4Ni=>
SNU-216 M1nq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXTWHBKSzVyPUOwJO69VQ>? M3;4PFI1ODh6M{iy
NUGC-4 NID0Z2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LwOWlEPTB;M{Cg{txO MV:yOFA5QDN6Mh?=
SNU-5 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNyIN88US=> M3\ieVI1ODh6M{iy
GTL-16 NITrRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNyIN88US=> MUGyOFA5QDN6Mh?=
MKN74 M{DKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnxUXRKSzVyPUOwJO69VQ>? MWOyOFA5QDN6Mh?=
PAMC82 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS2TWM2OD1|MDFOwG0> MXKyOFA5QDN6Mh?=
LNCaP NFnvcmtHfW6ldHnvckBCe3OjeR?= MmrmOUDPxE1? M2rEOVAuOjRiaB?= MnHibY5lfWOnczDBT3RUPDd|IHHu[EBCU1SWM{C4JJBpd3OyaH;yfYxifGmxbjDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= M{nLVlI{QTZ4NkKx
C4-2  NHSzWJBHfW6ldHnvckBCe3OjeR?= NGLZVmk2KM7:TR?= MlmyNE0zPCCq NWntVmFJcW6mdXPld{BCU1SVNEezJIFv\CCDS2TUN|A5KHCqb4PwbI9zgWyjdHnvckBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NI\rO48zOzl4Nk[yNS=>
LNCaP M3\HN2Z2dmO2aX;uJGF{e2G7 NH\iUog2KM7:TR?= MV[wMVI1KGh? NVnYSnZ2cW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKHSqZTDkbZN1[WxiQVvUMZBifGi5YYmgZolwdWG{a3Xyd{BqdmOudXTpcochWFKDU{SwMEBmUUZ2RTygOGUuSlBzLDDtWG9TNCCjbnSgVFcxKFN4IHvpcoF{\SCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MlHKNlM6PjZ4MkG=
C4-2  NGPBfnVHfW6ldHnvckBCe3OjeR?= M3L1TFUh|ryP MlXKNE0zPCCq NVPuWHVMcW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKHSqZTDkbZN1[WxiQVvUMZBifGi5YYmgZolwdWG{a3Xyd{BqdmOudXTpcochWFKDU{SwMEBmUUZ2RTygOGUuSlBzLDDtWG9TNCCjbnSgVFcxKFN4IHvpcoF{\SCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NHrSU4gzOzl4Nk[yNS=>
LNCaP MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOxMVExODByIH7N MX6wMVMh\A>? M3nubIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MXuyN|k3PjZ{MR?=
C4-2  NHTrU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH1NU0yODByMDDuUS=> NULYfVEzOC1|IHS= M2e1WolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M2PyUVI{QTZ4NkKx
LNCaP NV7Q[4RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzNNVAxNTVyMECgcm0> NVPwVVRLPzJiaB?= NYPTXIlncW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kBk\WyuczD1coRmemexaX7nJINmdGxiZHXheIg> NFfESXUzOzl4Nk[yNS=>
C4-2  MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrzXmYyODBvNUCwNEBvVQ>? Mo\2O|IhcA>? NFG3NItqdmO{ZXHz[ZMhfGinIH\yZYN1cW:wIH;mJINmdGy|IIXu[IVz\2:rbnegZ4VtdCCmZXH0bC=> NUDIOXRnOjN7Nk[2NlE>
PC-3 MYrGeY5kfGmxbjDBd5NigQ>? MX:wMlUwOS9zMDFOwG0> MU[0PEBp NUXOSWxt\G:5boLl[5Vt[XSnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKGSxd37zeJJm[W1icHH0bJdigSCycn;0[YlveyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWiyN|I2QDd2MB?=
DU145  MUDGeY5kfGmxbjDBd5NigQ>? NHzBTo8xNjVxMT:xNEDPxE1? MUK0PEBp NFvtVVVld3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4Yh\G:5boP0doVidSCyYYToe4F6KHC{b4TlbY5{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{DHSlI{OjV6N{Sw
LNCaP NVvHdI1OS2WubDDWbYFjcWyrdImgRZN{[Xl? MoWyNE0yODByIH7N NVT4Z5RmOC12IHS= M3TJT5Jm\HWlZXSgUG5E[VBiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVzyqB? MYOyN|I2QDd2MB?=
PC-3  NUn4XFRwTnWwY4Tpc44hSXO|YYm= M3y1TlExKM7:TR?= M4jjelEzKGh? M1Pud4lv\HWlZYOgZZV1d3CqYXf5 MX:yN|I2QDd2MB?=

... Click to View More Cell Line Experimental Data

体内研究 AZD5363按100, 300 mg/kg剂量口服给药裸鼠,降低BT474c移植瘤中PRAS40, GSK3β,和 S6的磷酸化,这种作用具有剂量和时间依赖性,也可逆性地增加血糖浓度,且降低U87-MG移植瘤中2[18F]氟-2-脱氧-d-葡萄糖(18F-FDG)的摄取,这种作用存在剂量依赖性。AZD5363按130, 200, 和300 mg/kg剂量慢性口服给药从各种肿瘤类型衍生的移植瘤,包括抗Trastuzumab的HER2+乳腺癌模型,抑制移植瘤的生长,这种作用存在剂量依赖性。AZD5363在乳腺癌移植瘤中也显著增强 Docetaxel, Lapatinib, 和 Trastuzumab的抗肿瘤活性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

Caliper Off-Chip Incubation迁移率变动分析:

通过 Caliper Off-Chip Incubation迁移率变动分析测评AZD5363和其他化合物抑制AKT1, AKT2, 和 AKT3活性的能力。活跃的重组AKT1,AKT2,或AKT3与5-FAM标记的定制合成的肽底物,及浓度不断增加的抑制剂温育。最终反应包含1 到 3 nM AKT1, AKT2, 或AKT3 酶; 1.5 mM 肽底物; AKT亚型的ATP为Km; 10 mM MgCl2, 4 mM DTT, 100 mM HEPES, 及0.015% Brij-35。反应在室温下温育1小时,然后加入含100 mM HEPES, 0.015% Brij-35 溶液, 0.1% 涂层试剂, 40 mM EDTA, 和5% DMSO的buffer终止反应。使用Caliper LC3000分析实验板,进行肽底物的分离,对磷酸化的产物进行电泳和激光诱导荧光的检测和量化。
细胞实验: [2]
+ 展开
  • Cell lines: 182种实体和血液肿瘤细胞系
  • Concentrations: 0.003 μM-30 μM
  • Incubation Time: 72 小时
  • Method: 通过MTS和Sytox Green2种方法测定细胞增殖实验。细胞接种在96孔板中,在37°C下,含 5% CO2的环境中温育过夜。使用浓度为30 到 0.003μM的 AZD5363处理细胞72小时。对于MTS端点,通过CellTiter AQueous非放射性细胞增殖检测试剂测量细胞增殖。对于Sytox Green 端点,在TBS-EDTA buffer 中稀释的Sytox Green核酸染料加到细胞中(终浓度为0.13μM),使用Acumen Explorer测定死亡细胞数。通过加入Saponin(终浓度0.03%,在TBS-EDTA buffer中稀释)使细胞具有渗透性,温育过夜,并测量总细胞数。MTS 和Sytox Green 端点都是给药前测量,使用吸光度读数(MTS)或活细胞计数测定将实验组细胞的生长降低到未处理组细胞的一半所需要的浓度值。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 携带 BT474c, U87MG, KPL-4, HCC-1187 移植瘤的雌性裸鼠和雄性SCID小鼠
  • Formulation: 溶于 10% DMSO 25% w/v Kleptose HPB
  • Dosages: 130 mg/Kg-300 mg/Kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 86 mg/mL (200.5 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
1% CMC Na
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 428.92
化学式

C21H25ClN6O2

CAS号 1143532-39-1
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02451956 Recruiting Advanced Gastric Cancer Samsung Medical Center January 7 2015 Phase 2
NCT02299999 Recruiting Metastatic Breast Cancer UNICANCER|Fondation ARC|AstraZeneca April 7 2014 Phase 2
NCT01625286 Active not recruiting Advanced or Metastatic Breast Cancer|ER+ve Advanced or Metastatic Breast Cancer AstraZeneca October 3 2012 Phase 1|Phase 2
NCT02121639 Recruiting Prostate Cancer University Hospital Southampton NHS Foundation Trust|AstraZeneca|Cancer Research UK January 29 2014 Phase 1|Phase 2
NCT02117167 Recruiting Non-small Cell Lung Cancer Metastatic UNICANCER|IFCT|Fondation ARC|AstraZeneca April 23 2014 Phase 2
NCT02576444 Recruiting Cancer Joseph Paul Eder|Dana-Farber Cancer Institute|Vanderbilt-Ingram Cancer Center|The Cleveland Clinic|Yale University November 2015 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

相关Akt产品

Tags: 购买AZD5363 | AZD5363供应商 | 采购AZD5363 | AZD5363价格 | AZD5363生产 | 订购AZD5363 | AZD5363代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID